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Pemphigoid gestationis (PG) is a pregnancy-associated 
blistering autoimmune skin disease, which most com-
monly erupts between the second trimester and the 
puerperium (1, 2). PG presents with pruritus and erythe-
matous papules, urticarial erythema, and papulovesicles, 
as well as, in rare cases, blistering. Skin lesions predomi-
nantly arise initially on the periumbilical region. Onset 
of PG in the first or second trimester, as well as presence 
of blisters, are associated with adverse pregnancy out-
comes (3). PG is driven by auto-antibodies directed to 
the hemidesmosomal adhesion molecule BP180. IgG 
auto-antibodies directed against the NC16A domain of 
BP180 can be found in 90% of patients with PG and, in 
some cases, remain positive after delivery (4–8). Auto-
antibodies against a second hemidesmosomal protein, 
BP230, have been reported in up to 16% of PG sera (9), 
but the frequency of anti-BP230 auto-antibodies in 
healthy controls was not determined in this Japanese 
study. Detection of serum anti-BP180 NC16A IgG auto-
antibodies by enzyme-linked immunoassay (ELISA) 
is the most convenient diagnostic method for PG. An 
alternative approach is the detection of auto-antibodies 
and complement at the dermoepidermal junction (DEJ) 
by direct immunofluorescence (DIF).
Recently, BIOCHIP® mosaic-based indirect IF mi-
croscopy has emerged as novel technique for the detec-
tion of skin protein-directed auto-antibodies in routine 
laboratory use (10, 11). Its validity for the diagnosis 
of PG, however, has not been investigated. Herein we 
report that detection of anti-BP180 auto-antibodies by 
BIOCHIP® mosaics is both highly sensitive and specific 
in discriminating patients with PG from healthy controls. 
MATERIALS AND METHODS
Sera from a total of 65 patients with PG were collected at the uni-
versity hospitals of Lübeck (n = 14), Groningen (n = 26), Munich 
(LMU) (n = 10), Würzburg (n = 11) and Vienna (n = 4). Criteria 
for inclusion of patients with PG were a clinical presentation 
compatible with PG and a positive complement-binding test 
and/or anti-BP180 NC16A IgG enzyme-linked immunoassay 
(ELISA) results. Positive DIF microscopy results were not used 
as inclusion criterion, with DIF microscopy in clinical practice 
often avoided due to the requirement for skin biopsy. All clinical 
and laboratory details on the patients are summarized in Table SI1. 
Sera from healthy para, taken in the first 24 h of the puerperium 
at the Department of Gynecology and Obstetrics, Lübeck, served 
as control (n = 102). All sera were stored between –80 and –20°C 
until use. The study was approved by the ethics committee of the 
University of Lübeck (12-178; 14-227).
All sera were subjected to the BIOCHIP® mosaic (Euroimmun, 
Lübeck, Germany) with 4 different substrates per incubation field, 
including primate split-skin, monkey oesophagus, recombinant 
tetrameric BP180 NC16A, and HEK293 cells expressing the 
C-terminal globular domain of BP230 (BP230 gC; amino acids 
1875–2649) on the cell surface (10, 11). The BIOCHIP® mosaic 
assay specifically detects IgG auto-antibodies bound to the respec-
tive auto-antigens. Circulating anti-BP230 IgG auto-antibodies 
were determined in parallel by 2 different ELISA systems, using 
an E. coli-expressed fragment of the C-terminal globular domain 
of BP230 (Euroimmun; BP230-C; amino acids 2326–2649) and 
both the recombinant N- and C-terminal fragments (MBL, Nagoya, 
Japan; BP230-N-C; amino acids 1–979 and 1869–2649) (12, 
13). All assays were performed according to the manufacturers’ 
instructions.
Data were analysed using GraphPad 7 software (GraphPad, San 
Diego, USA) and tested for statistical significance using Fisher’s 
exact test. p < 0.05 was defined as statistically significant.
RESULTS
Sera from patients with PG and control para were screened 
for auto-antibodies using BIOCHIP® mosaics (Table I). 
In this assay, 57 (87%) sera from patients with PG were 
reactive on salt-split skin and 65 (100%) with BP180 
NC16A. In the control group, only one (1%) serum was 
positive on salt-split skin and none of the sera contained 
anti-BP180 NC16A auto-antibodies (Table I). Thus, salt-
split skin had a sensitivity of 0.88 and a specificity of 0.99 
in distinguishing patients with PG from healthy controls, 
while detection of anti-BP180 auto-antibodies by BIO-
CHIP® mosaic resulted in the distinction of patients with 
PG and healthy controls with a sensitivity and specificity 
of 1.0. The BIOCHIP® mosaic detected anti-BP230 auto-
antibodies in sera of 13 (20%) patients with PG and of 5 
(5%) controls, a sensitivity of 0.20 and specificity of 0.95 
(Table I). As the frequency of anti-BP230 auto-antibodies 
in patients with PG is still controversially debated, we 
also determined anti-BP230 auto-antibodies by the com-
mercially available BP230-C and BP230-N-C ELISA 
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sets. With the BP230-N-C ELISA, anti-BP230 reactivity 
was found in 7 (11%) PG sera and in 6 (6%) control sera, 
whereas in the BP230-C ELISA, none of the patients with 
PG and only 1 (1%) of the control samples were positive 
(Table I). Of note, none of the patient or control samples 
was positive in more than 1 of 3 assays for anti-BP230 
auto-antibodies. Notably, when a positive DIF microscopy 
was used as mandatory inclusion criterion, the major 
results of our evaluation did not change (Table SII1). A 
database search in Groningen and Lübeck identified 4 
patients with PG with positive DIF microscopy and no 
reactivity for anti-BP180 auto-antibodies in the ELISA. 
Notably, all 4 patients were also negative for anti-BP230 
auto-antibodies. 
DISCUSSION
This study established the validity of the BIOCHIP® 
mosaic in the serological diagnosis of PG. The complete 
absence of anti-BP180 IgG auto-antibodies in healthy 
para is in line with previous reports on the frequency of 
anti-BP180 IgG auto-antibodies in healthy blood donors 
and in healthy pregnant women (14, 15), indicating that 
anti-BP180 NC16A IgG auto-antibodies do not emerge 
in healthy pregnancies. However, in some patients 
with PG, low titres of anti-BP180 auto-antibodies were 
detectable by ELISA, but mostly remained too low to 
reach the assay’s cut-off value (7). This phenomenon 
conceivably leads to falsely diagnosed cases of PG in 
patients who have had PG during a previous pregnancy, 
but who now have a different pregnancy-associated 
dermatosis, while still being anti-BP180 auto-antibody 
positive (7). Although we cannot fully exclude that our 
study included such patients, it is highly unlikely that 
these patients are more than a negligible percentage of 
the patients in this study. 
Our results highlight the BIOCHIP® mosaic as an 
alternative to the complement-binding test and to anti-
BP180 NC16A ELISAs. The general advantage of the 
BIOCHIP® mosaic is that it facilitates the usual multistep 
laboratory diagnostic of autoimmune blistering skin 
diseases into a single, easily to perform, assay. Further-
more, BIOCHIP® mosaic enables simultaneous screening 
for several auto-antibody species. 
Although anti-BP230 auto-antibodies have been 
reported to be present in some patients with PG, the 
frequency of anti-BP230 auto-antibody formation in PG 
and its diagnostic and prognostic value have remained 
controversial. In our study, the percentage of anti-BP230 
auto-antibody-positive individuals among both patients 
with PG and controls varied considerably depending 
on the immunoassay used and, when compared, the 
assays continuously delivered conflicting results. This 
discrepancy may be explained by the different BP230 
fragments used as target structure in these assays. 
While the BP230-N-C ELISA detects anti-BP230 IgG 
antibodies directed against both the N- and C-terminal 
portions of BP230, the BP230-C ELISA only detects 
auto-antibodies against a small specific fraction of the 
C-terminal end. On the BIOCHIP®, in contrast, the entire 
globular C-terminal end of BP230, expressed in HEK293 
cells, is presented (11). This notion is supported by the 
finding that none of the PG and control sera was positive 
for anti-BP230 antibodies in more than 1 assay system. 
Hence, all 3 anti-BP230 IgG assays must be considered 
to be of poor diagnostic value in PG, and positive anti-
BP230 IgG auto-antibody results by either test must be 
interpreted with caution. 
In summary, the BIOCHIP® mosaic can be used ins-
tead of the corresponding ELISA systems when absolute 
quantification of auto-antibody levels is not required. 
Furthermore, detection of anti-BP230 auto-antibodies 
does not add to the diagnosis of PG, when anti-BP180 
and/or the complement-binding test are performed. By 
design, our study cannot exclude that the detection of 
anti-BP230 auto-antibodies may be instrumental in iden-
tifying a subgroup of patients with PG with typical clini-
cal PG presentation and positive DIF microscopy, but 
without detectable levels of anti-BP180 auto-antibodies.
The authors declare no conflicts of interest.
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